Physician
Joslyn, Matthew
Joslyn, Matthew was paid $282K by Medicaid between Jan 2018 and Sep 2022, across 9 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 40% of everything it billed.
33Billing provider infoJOSLYN, MATTHEW
BOSTON, MA 02118
BOSTON, MA 02118
33aNPI1659440790assigned 11/06/2006
33bProvider typeFamily Medicine Physician
28Total paid$282K
24GClaims5,290
24DCodes billed9
24AFirst – last monthJan 2018 – Sep 2022
Compared with peers
Next to other Family Medicine Physician providers in Massachusetts
Rank by total paid#69 of 744
Median peer was paid$10K
This provider vs. median27×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 812 | $48K | |
| 2019 | 1,267 | $69K | |
| 2020 | 442 | $22K | |
| 2021 | 1,455 | $76K | |
| 2022 | 1,314 | $66K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 40% | 2,482 | 1,552 | $113K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 37% | 1,852 | 1,290 | $103K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 758 | 412 | $59K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.2% | 100 | 85 | $6K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 19 | 19 | $417.43 |
| 86803 | <1% | 20 | 20 | $260.20 | |
| 87340 | <1% | 20 | 20 | $188.40 | |
| 81025 | <1% | 12 | 12 | $71.72 | |
| H0003 | Alcohol and/or drug screening; laboratory analysis of specimens for presence of alcohol and/or drugs | <1% | 27 | 25 | $0.27 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.